9 New ‘Vaccine Billionaires’ Amass Combined Net Worth of $19.3 Billion During Pandemic

A new report by People’s Vaccine Alliance reveals how Big Pharma’s monopoly on COVID vaccines generated a massive increase in wealth for a handful of people.

By Children’s Health Defense
Global Research, May 28, 2021
Children's Health Defense 25 May 2021
Region:
Theme:

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version). 

Visit and follow us on Instagram at @crg_globalresearch.

***

A new report shows the global push to develop a vaccine for COVID-19 has spawned nine new “vaccine billionaires” who have amassed a combined net wealth of $19.3 billion.

The author of the report, People’s Vaccine Alliance, said the pharmaceutical industry’s monopoly on COVID vaccines has generated a massive increase in wealth for a handful of people.

In addition to the nine new “vaccine billionaires,” the coalition of health and humanitarian organizations, world leaders and economists said “eight existing billionaires — who have extensive portfolios in the COVID-19 vaccine pharma corporations — have seen their combined wealth increase by $32.2 billion.”

Anna Marriott, health policy manager at Oxfam, a member of the People’s Vaccine Alliance, said:

“These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines. These vaccines were funded by public money and should be first and foremost a global public good, not a private profit opportunity.”

The coalition’s list of new vaccine billionaires includes four tycoons who profited off U.S. vaccine maker Moderna, the CEO of BioNTech and three co-founders of the Chinese vaccine company, CanSino Biologics.

The nine billionaires, in order of their net worth are:

  1. Stéphane Bancel, CEO of Moderna, now worth $4.3 billion.
  2. Ugur Sahin, CEO and co-founder of BioNTech, now worth $4 billion.
  3. Timothy Springer, immunologist and founding investor of Moderna, now worth $2.2 billion.
  4. Noubar Afeyan, Moderna’s chairman, now worth $1.9 billion.
  5. Juan Lopez-Belmonte, chairman of spanish drugmaker Rovi, which struck a deal to make ingredients for Moderna’s vaccine, now worth $1.8 billion.
  6. Robert Langer, scientist and founding investor in Moderna, worth $1.6 billion.
  7. Zhu Tao, co-founder and chief scientific officer at CanSino Biologics, worth $1.3 billion.
  8. Qiu Dongxu, co-founder and senior vice president at CanSino Biologics, now worth $1.2 billion.
  9. Mao Huihua, co-founder and senior vice president at CanSino Biologics, now worth $1 billion.

The eight existing billionaires whose wealth soared during the pandemic include investors with stock in pharma companies that hold a monopoly on COVID vaccines.

The list includes Indian billionaire Pankaj Patel, chairman of Cadila Healthcare, a pharma company that makes drugs such as Remdesivir to treat COVID and has a vaccine undergoing clinical trials.

Also on the list is Patrick Soon-Shiong, a medical doctor whose COVID vaccine, ImmunityBio, was selected by the U.S. government’s “Operation Warp Speed,” a program to accelerate the rollout of COVID vaccines.

The new vaccine billionaires join the ranks of other ultra-rich elite, who also profited off the pandemic. They include Tesla’s Elon Musk, Amazon’s Jeff Bezos, Facebook’s Mark Zuckerberg, Microsoft’s Bill Gates and Google co-founders Larry Page and Sergey Brin — all of whom made Forbes’ top 10 Big Billionaire Gains list, adding a “collective $488 billion to their fortunes since the beginning of 2020.”

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Children’s Health Defense

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]